Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abbisko Cayman Limited ( (HK:2256) ) has issued an update.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received clearance from the U.S. FDA for its Investigational New Drug application for ABSK141, a novel oral small-molecule KRAS G12D inhibitor. This development marks a significant step in addressing the challenging KRAS G12D mutation found in various solid tumors, including pancreatic, colorectal, and non-small cell lung cancers. The IND clearance allows Abbisko to proceed with Phase I/II clinical trials to evaluate the drug’s safety and efficacy, potentially strengthening its position in the oncology pharmaceutical industry.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company dedicated to discovering and developing innovative medicines for unmet medical needs in China and globally. The company has built a pipeline of programs focused on precision oncology and immuno-oncology.
Average Trading Volume: 3,894,830
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.73B
For a thorough assessment of 2256 stock, go to TipRanks’ Stock Analysis page.